Health & Pharma
Why the Liver Test Became the Real Contest in a Rare Joint Tumor
A third oral drug for a rare joint tumor cleared the FDA with the highest response rate yet and no boxed liver warning. In a market measured in thousands of patients a year, the label may matter more than the trial result.
- Bayer's First-Ever Factor XIa Drug Rebuilds a Shrunken Blockbuster Bet
- CVS Is Unwinding the Deal That Built It
- J&J's Rybrevant Wins the First New Second-Line Head and Neck Cancer Drug in a Decade
- FDA Approves the First DNA-Based Immunotherapy, on a 32-Patient Trial
- A Catholic Nonprofit Is Taking Surgery Partners Private
- Hepatitis B's First Functional Cure Reaches the US Market
- AstraZeneca's Ultomiris Cuts IgAN Proteinuria 43%, but the Kidney Proof Is Still Pending
- GSK's New Drug Could Spare Rectal Cancer Patients Surgery






















































